Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and ...

Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent(dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in ...

Treating atopic dermatitis (AD) with dupilumab vs other systemic agents increased the risk of developing psoriasis over 3 years, a cohort study found. Addressing postmarketing reports of psoriasis ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...